"Tetrahydronaphthalenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Partially saturated 1,2,3,4-tetrahydronaphthalene compounds.
| Descriptor ID |
D013764
|
| MeSH Number(s) |
D02.455.426.559.847.638.960 D04.615.638.960
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tetrahydronaphthalenes".
Below are MeSH descriptors whose meaning is more specific than "Tetrahydronaphthalenes".
This graph shows the total number of publications written about "Tetrahydronaphthalenes" by people in this website by year, and whether "Tetrahydronaphthalenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tetrahydronaphthalenes" by people in Profiles.
-
Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann Oncol. 2014 Jan; 25(1):206-10.
-
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
-
Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor ?-dependent mechanism. Mol Pharmacol. 2012 Feb; 81(2):228-38.
-
Erythema gyratum repens-like eruptions with large cell transformation in a patient with mycosis fungoides. Int J Dermatol. 2012 Oct; 51(10):1231-3.
-
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila). 2011 Jun; 4(6):818-28.
-
Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011 May; 12(5):496-503.
-
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010 Nov 17; 102(22):1706-15.
-
Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol. 2009 Oct; 61(4):592.e1-9.
-
Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila). 2009 Feb; 2(2):168-74.
-
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model. Cancer Prev Res (Phila). 2009 Feb; 2(2):175-84.